Boehringer Ingelheim's Phase II Agent Could Be The First Second-Wave Protease Inhibitor For Hep C
This article was originally published in The Pink Sheet Daily
Executive Summary
BI's '355 has impressive response rates in early studies, but jaundice is a concern.